Another brain-penetrant small molecule inhibitor of RIPK1 is DNL747, also known as SAR443060 (reducing RIPK1 phosphorylation at Ser166), which has also completed phase I safety, tolerability, pharmacokinetics, and pharmacodynamics trials in AD or ALS patients (ClinicalTrials.gov identifier: NCT03757325, NCT03757351). This evidence concerns the gene RIPK1 and amyotrophic lateral sclerosis.